Yuyu Pharma Signs Domestic Distribution and Sales Agreement for 5 Novartis Prescription Drugs

[Asia Economy Reporter Seo So-jeong] Yuyu Pharmaceutical (CEO Yoo Won-sang) announced on the 22nd that it has signed an exclusive domestic sales contract with Korea Novartis for five prescription drugs, including the antifungal treatment 'Lamisil', the dyslipidemia treatment 'Lescol', and the epilepsy treatment 'Tegretol' series.

Starting from the 1st of next month, Yuyu Pharmaceutical will solely handle the distribution, sales, and marketing promotions of these five prescription drugs at all hospitals and clinics nationwide.

Lamisil tablets contain terbinafine hydrochloride as a single ingredient and are prescription antifungal drugs used to treat tinea pedis, tinea corporis, tinea cruris (jock itch), and onychomycosis (fungal infections of the nails).

Lescol XL extended-release tablets contain fluvastatin sodium as a single ingredient and are prescribed for primary hypercholesterolemia and to delay the progression of coronary atherosclerosis in patients with coronary artery disease, reduce the risk of recurrent cardiac events after percutaneous coronary intervention in coronary artery disease patients, and treat hyperlipidemia.

Tegretol contains carbamazepine as a single ingredient and is a prescription drug used for epilepsy (seizures), trigeminal neuralgia, manic episodes of bipolar disorder, and excited states of schizophrenia. It is available as Tegretol CR tablets, Tegretol tablets, and Tegretol syrup.

Yoo Won-sang, CEO of Yuyu Pharmaceutical, stated, "With the expansion of our prescription drug lineup that can create synergy with existing products, we are now able to supply products that meet the demands of medical professionals according to various clinical situations in the field."

This content was produced with the assistance of AI translation services.